An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602

Trial Profile

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602

Suspended
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 602
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Sep 2017 Status changed from active, no longer recruiting to suspended, according to a Bristol-Myers Squibb media release.
    • 06 Sep 2017 According to a Bristol-Myers Squibb media release,the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on this trial because of risks identified in trials studying another anti PD1 agent, pembrolizumab, in patients with multiple myeloma.
    • 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top